Ian M. Colrain, Ph.D. Joins from SRI International, Will Begin July 1
The MRIGlobal Board of Directors today announced on June 9 that Ian M. Colrain, Ph.D., has been named president and chief executive officer of MRIGlobal, and will assume the role beginning July 1. With the appointment, Colrain assumes responsibility of all operations for MRIGlobal. Colrain was previously with SRI International (formerly Stanford Research Institute) as president of SRI Biosciences, where he led the strategic planning, business development and research operations for a multidisciplinary team of more than 250 employees with top- and bottom-line responsibility for its $75 million annual operating budget.
Colrain succeeds Thomas M. Sack, who was named president and CEO in 2013, and will be retiring from MRIGlobal at the end of June after more than 40 years with the institute.
“We’re excited to welcome Ian to MRIGlobal. He brings incredible passion, strong business acumen, and a depth of experience to this position,” said David Oliver, Chairman of the MRIGlobal Board of Directors. “The past five years have been the most successful in MRIGlobal’s 78-year history. We believe Ian’s leadership will strengthen our ability to continue solving the difficult challenges of our customers and propel the institute to realize even greater success.”
“MRIGlobal is well-positioned financially, technically, and contractually, with the right customers and a tremendous reputation, to expand its market share,” Colrain said. “Coupled with an outstanding team of researchers and support staff, we have an incredible opportunity to build upon recent success and further expand our positive impact globally. I look forward to leading MRIGlobal as we solve the world’s most challenging problems in defense and health.”
In this role, Colrain will also become involved with the Alliance for Sustainable Energy, LLC, which manages more than $550 million in research at the National Renewable Energy Laboratory (NREL) in Golden, Colo., for the U.S. Department of Energy. NREL is co-managed by MRIGlobal.
Colrain led SRI Biosciences from a “non-profit pharma, one drug per bug” model to being more focused on platform development for drug discovery and targeted drug delivery. This has led to multiple licensing deals that have the potential to generate tens of millions of dollars in royalty revenue for SRI.
It is also notable that Colrain played a leading role in developing the diversity, equity, and inclusion strategy for SRI International, and ran the most diverse division in the institute, with the highest proportion of women in senior roles. He will be fully committed to ensuring that we recruit a diverse workforce, treat everyone with equity, and have a work environment in which all feel welcome and included.
Getting started with MRIGlobal
As a not-for-profit contract research organization, we have proven ourselves as an objective partner driven to make our clients’ products more successful. We specialize in defense, human health, pharmaceutical sciences, in-vitro diagnostics, energy and environment, agriculture, and global health.
To learn more about the work we’ve done or how we can help you, contact us today. If you are part of an agency, business, or academic institution seeking assistance with a project, use our Project Quote Tool to get started.